Sinopharm Group Co (Sinopharm Group Co) Total Stockholders Equity : $0 Mil (As of Sep. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co Total Stockholders Equity?

Sinopharm Group Co's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $0 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Sinopharm Group Co's Book Value per Share for the quarter that ended in Sep. 2023 was $N/A. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Sinopharm Group Co's Debt-to-Equity for the quarter that ended in Sep. 2023 was .

Sinopharm Group Co Total Stockholders Equity Historical Data

The historical data trend for Sinopharm Group Co's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co Total Stockholders Equity Chart

Sinopharm Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

6,761.36

8,618.48

9,716.30

9,763.55

10,445.40

Sinopharm Group Co Quarterly Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial															-	9,763.55	9,719.40	-	10,445.40

Sinopharm Group Co (OTCPK:SHTDF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Sinopharm Group Co's Book Value per Share for the quarter that ended in Sep. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(0	-	0)	/	3120.66
	=	N/A

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Sinopharm Group Co's Debt-to-Equity for the quarter that ended in Sep. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	0
	=

Sinopharm Group Co Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinopharm Group Co (Sinopharm Group Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (OTCPK:SHTDF) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

SHTDY:USA 01099:Hong Kong X2S:Germany

Address

No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023

Website

http://www.sinopharmgroup.com.cn

Sinopharm Group was founded in 2003 and listed on the Hong Kong Stock Exchange in September 2009. Its main business is drug distribution in mainland China, which contributes about 75% of total revenue. It is the largest drug distributor, with approximately 20% market share. Other notable segments are medical device distribution, which contributes about 20% of revenue, and retail pharmacies, which contributes about 5%. These are fast-growing industries, where government policy is designed to encourage consolidation and promote large players with scale and efficiency advantages.

Sinopharm Group Co (Sinopharm Group Co) Headlines

From GuruFocus

Matthews China Fund Comments on Sinopharm Group

By Vera Yuan Vera Yuan • 10-20-2014

Matthews China Fund 1st Quarter Commentary

By Holly LaFon Holly LaFon • 05-19-2016

Matthews China Fund Q3 2014 Commentary

By Holly LaFon Holly LaFon • 10-18-2014

Arnold Van Den Berg Buys Prem Watsa's Fairfax India, 3 Other Stocks in 3rd Quarter

By Holly LaFon Holly LaFon • 10-31-2017

Matthews China Fund Comments on Sinopharm

By Holly LaFon Holly LaFon • 05-19-2016

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood • 07-30-2020

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood • 01-25-2021